Actively Recruiting
PSMA in Gastroenterologic Tumors (GIPSMA)
Led by Wuerzburg University Hospital · Updated on 2025-09-29
46
Participants Needed
1
Research Sites
208 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The theranostic principle is based on the use of radiolabeled compounds which can be applied for diagnostic molecular imaging and targeted delivery of radiation to the tumor. Gastroenterologic tumors (GET), including hepatocellular Carcinoma, Colorectal Carcinoma, Pancreatic Adenocarcinoma, Cholangiocellular Carcinoma, gastroenteropancreatic neuroendocrine neoplasms also express a phenotypic biomarker called prostate-specific membrane antigen (PSMA), thereby rendering it a potential diagnostic (through positron emission tomography (PET) scan imaging) and therapeutic target for radioligand therapy. Aim is to evaluate whether PSMA-directed in-vivo imaging can be also applied to GET patients to determine if i) biopsy-derived tissue of newly diagnosed patients exhibit a PSMA expression profile, ii) PSMA-PET shows upregulated PSMA expression in-vivo, iii) such a molecular imaging approach identifies more disease sites relative to conventional imaging, and iv) if the PSMA PET signal predicts further clinical course and outcome under guideline-compatible treatment.
CONDITIONS
Official Title
PSMA in Gastroenterologic Tumors (GIPSMA)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with newly diagnosed gastroenterologic tumors before starting guideline-compatible anti-tumor therapy
- Available tissue specimen for PSMA expression profiling
- Male or female patients aged 18 years or older
- Patients able and willing to provide written informed consent
- Patients willing to follow study procedures and available for follow-up examinations
You will not qualify if you...
- Patients in a curative treatment setting
- Insufficient tumor tissue available for analysis
- Male patients without prostate carcinoma
- History of other malignant cancers
- Pregnancy or breastfeeding
- Contraindications to PET/CT imaging
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University Hospital Wuerzburg
Würzburg, Bavaria, Germany, 97080
Actively Recruiting
Research Team
A
Alexander M Weich, MD
CONTACT
R
Rudolf A Werner, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here